Sugi Predict

Sugi Predict / Compounds / Guanine

Guanine

Guanine

SCHEMBL79001

Nc1cc[nH]c(=O)n1.Nc1nc2nc[nH]c2c(=O)[nH]1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 2/20 0.72
▸ ALDH1A1 P00352 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ GRIA1 P42261 1/20 0.45
▸ GRIA2 P42262 1/20 0.45
▸ GRIA3 P42263 1/20 0.45
▸ GRIA4 P48058 1/20 0.45
▸ DYRK1A Q13627 1/20 0.44
▸ GDA Q9Y2T3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanine SCHEMBL2529420 1.00 PNP (0.72) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL2528337 1.00 PNP (0.72) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL23576542 0.94 PNP (0.63) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL19991865 0.93 PNP (0.62) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL5579240 0.92 PNP (0.60) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL7211609 0.92 PNP (0.60) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL37966 0.91 PNP (0.59) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL20518478 0.88 PNP (0.55) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL17597606 0.88 PNP (0.55) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL23880590 0.88 PNP (0.55) PNPALDH1A1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 596 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250268994-A1 Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof TRANSLATE BIO, INC. (US) 2025-08-28 — — US claimed
US-12203083-B2 Programmable epigenetic control of gene expression in plants DECIBEL BIO, INC (US) 2025-01-21 — — US claimed
US-12195724-B2 Methods of producing T cell populations enriched for stable regulatory T-cells THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-01-14 — — US claimed
US-20240342269-A1 OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING SARS-COV-2 ANTIGENS TRANSLATE BIO, INC. 2024-10-17 — — US claimed
CN-112201307-B Transcript annotation method and method for screening long non-coding RNA and endogenous retrovirus-derived long non-coding RNA 温州医科大学 2024-09-17 — — CN claimed
CN-117736984-A Regulatory B cell producing interleukin-37 and preparation method and application thereof 深圳大学 2024-03-22 — — CN claimed
EP-4313115-A1 OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING THE EXTRACELLULAR DOMAIN OF HUMAN ACE2 PROTEIN OR A PORTION THEREOF Translate Bio, Inc. (US) 2024-02-07 — — EP claimed
US-11802303-B2 Methods for multiplexed cell isolation using DNA gates GEORGIA TECH RESEARCH CORPORATION (US) 2023-10-31 — — US claimed
US-20230304028-A1 PROGRAMMABLE EPIGENETIC CONTROL OF GENE EXPRESSION IN PLANTS Sound Agriculture Company (US) 2023-09-28 — — US claimed
CN-116710557-A Optimized nucleotide sequence for coding SARS-COV-2 antigen 翻译生物公司 2023-09-05 — — CN claimed
US-9382308-B2 CD133 epitopes CEDARS-SINAI MEDICAL CENTER (US) 2016-07-05 — — US claimed
US-9068020-B2 CD133 epitopes CEDARS-SINAI MEDICAL CENTER (US) 2015-06-30 — — US claimed
US-20150118183-A1 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION CUREVAC GMBH (DE) 2015-04-30 — — US claimed
EP-2809354-A1 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION Curevac GmbH (DE) 2014-12-10 — — EP claimed
US-20130236496-A1 USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE UNIVERSITE DE LAVAL (CA) 2013-09-12 — — US claimed
WO-2013113502-A1 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION CUREVAC GMBH (DE) 2013-08-08 — — WO claimed
US-20130183378-A1 CD133 Epitopes CEDARS-SINAI MEDICAL CENTER (US) 2013-07-18 — — US claimed
WO-2012000082-A1 USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-L-LIKE RECEPTOR LIGAND OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE UNIVERSITé LAVAL (CA) 2012-01-05 — — WO claimed
CN-1554359-A Process for preparing cytosine suanine dinuleotide sequence molecule immunopotentiator 广东省农业科学院农业生物技术研究所 2004-12-15 — — CN claimed
US-5077196-A Arabinonucleic acid segment-containing probes for DNA/RNA assays E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-12-31 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342269-A1 OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING SARS-COV-2 ANTIGENS ACE2, TMPRSS2, SARS1 PNP 212/4885ALDH1A1 4808/4885KDM4E 4716/4885
US-20250268994-A1 Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof ACE2, LNPEP, ACE PNP 190/4885ALDH1A1 4194/4885KDM4E 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.